Drug Profile
Glesatinib companion diagnostic - Mirati Therapeutics/QIAGEN
Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator QIAGEN
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in Germany
- 28 May 2019 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in USA